Tumor-conditional IL-15 pro-cytokine reactivates anti-tumor immunity with limited toxicity

Jingya Guo,Yong Liang,Diyuan Xue,Jiao Shen,Yueqi Cai,Jiankun Zhu,Yang-Xin Fu,Hua Peng
DOI: https://doi.org/10.1038/s41422-021-00543-4
IF: 44.1
2021-08-10
Cell Research
Abstract:IL-15 is a promising cytokine to expand NK and CD8+ T cells for cancer immunotherapy, but its application is limited by dose-limiting, on-target off-tumor toxicity. Here, we have developed a next-generation IL-15 that is activated inside the tumor microenvironment (TME). This pro-IL-15 has the extracellular domain of IL-15Rβ fused to the N-terminus of sIL-15-Fc through a tumor-enriched Matrix Metalloproteinase (MMP) cleavable peptide linker to block its activity. Unlike sIL-15-Fc, pro-IL-15 does not activate the peripheral expansion of NK cells and T cells, thus reducing systemic toxicity, but it still preserves efficient anti-tumor abilities. In various mouse tumors, the anti-tumor effect of pro-IL-15 depends on intratumoral CD8+ T cells and IFN-γ. Pro-IL-15 increases the stem-like TCF1+Tim-3−CD8+ T cells within tumor tissue and helps overcome immune checkpoint blockade (ICB) resistance. Moreover, pro-IL-15 synergizes with current tyrosine kinase inhibitor (TKI) targeted-therapy in a poorly inflamed TUBO tumor model, suggesting that pro-IL-15 helps overcome targeted-therapy resistance. Our results demonstrate a next-generation IL-15 cytokine that can stimulate potent anti-tumor activity without severe toxicity.
cell biology
What problem does this paper attempt to address?
The problem that this paper attempts to solve is: how to reduce the dose - limiting systemic toxicity while improving the efficacy of IL - 15 for cancer immunotherapy. Specifically, the researchers developed a novel IL - 15 precursor protein (pro - IL - 15), which can be specifically activated in the tumor microenvironment, thus avoiding the severe side effects caused by excessive activation of peripheral lymphocytes in traditional IL - 15 treatment. In this way, pro - IL - 15 can not only effectively inhibit tumor growth, but also overcome the resistance of immune checkpoint blockade (ICB) and tyrosine kinase inhibitor (TKI) therapies while maintaining low systemic toxicity. ### Main problem analysis: 1. **Clinical application limitations of IL - 15**: - **Short half - life**: IL - 15 is rapidly degraded in the body, which limits its efficacy. - **Inefficiency**: The effect in the treatment of solid tumors is not satisfactory. - **Dose - limiting toxicity**: Since IL - 15 binds to peripheral lymphocytes, it causes severe systemic toxicity, such as weight loss and reduced survival rate. 2. **Design goals of pro - IL - 15**: - **Specific activation in the tumor microenvironment**: By fusing the extracellular domain of the IL - 15 receptor β chain with sIL - 15 - Fc and using an MMP - 14 - cleavable peptide chain as a linker, pro - IL - 15 is activated in the tumor microenvironment, thereby reducing the activation of peripheral lymphocytes. - **Reducing systemic toxicity**: Through the above design, pro - IL - 15 can significantly reduce the non - specific amplification of peripheral NK cells and T cells, thereby reducing systemic toxicity. - **Enhancing anti - tumor effects**: Pro - IL - 15 exhibits highly efficient anti - tumor activity in multiple mouse tumor models, especially by activating CD8+T cells and IFN - γ production in tumors. 3. **Mechanism verification of pro - IL - 15**: - **In vivo distribution**: Through fluorescence labeling and imaging techniques, it has been confirmed that pro - IL - 15 can specifically accumulate in tumor tissues. - **Cytotoxicity test**: Through blood tests and histopathological analysis, it has been proven that pro - IL - 15 does not cause significant organ inflammation or damage. - **Immune cell function**: By depleting different types of immune cells, it has been confirmed that CD8+T cells play a key role in the pro - IL - 15 - mediated anti - tumor effect. 4. **Potential of combination therapy**: - **Combined with ICB**: The combined use of pro - IL - 15 and PD - 1/PD - L1 antibodies can significantly enhance the anti - tumor effect and overcome the resistance of single - treatment. - **Combined with TKI**: The combined use of pro - IL - 15 and tyrosine kinase inhibitors can effectively control the growth of refractory tumors and prevent recurrence. ### Conclusion: By designing and validating pro - IL - 15, the researchers have successfully developed an IL - 15 precursor protein that can be specifically activated in the tumor microenvironment, which not only improves the anti - tumor effect but also significantly reduces systemic toxicity. This finding provides new strategies and tools for future cancer immunotherapy.